

Company Number: 490385

Bridge St. Pharmacy Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 December 2025

Bridge St. Pharmacy Limited

CONTENTS

	Page
Directors and Other Information	3
Directors' Responsibilities Statement	4
Balance Sheet	5 - 6
Statement of Changes in Equity	7
Notes to the Financial Statements	8 - 11

Bridge St. Pharmacy Limited
DIRECTORS AND OTHER INFORMATION

Directors Edmond McElligott
Mary McElligott

Company Number 490385

Registered Office Bridge Street
Abbeyfeale
Co. Limerick

Business Address Bridge Street
Abbeyfeale West
Abbeyfeale
Co. Limerick

Accountants FDC Group
Mangerton House
St. Anthony's Place
Killarney
Co. Kerry

Bridge St. Pharmacy Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Edmond McElligott
Director

31 March 2026

Mary McElligott
Director

31 March 2026

Bridge St. Pharmacy Limited
BALANCE SHEET

as at 31 December 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	5	<u>75,186</u>	<u>88,162</u>
Current Assets			
Stocks	6	111,762	136,649
Debtors	7	149,314	131,844
Cash and cash equivalents		<u>1,745,372</u>	<u>1,524,916</u>
		<u>2,006,448</u>	<u>1,793,409</u>
Creditors: amounts falling due within one year	8	<u>(87,317)</u>	<u>(118,783)</u>
Net Current Assets		<u>1,919,131</u>	<u>1,674,626</u>
Total Assets less Current Liabilities		<u><u>1,994,317</u></u>	<u><u>1,762,788</u></u>
Equity			
Called up share capital presented as equity		20	20
Retained earnings		<u>1,994,297</u>	<u>1,762,768</u>
Equity attributable to owners of the company		<u><u>1,994,317</u></u>	<u><u>1,762,788</u></u>

Bridge St. Pharmacy Limited

BALANCE SHEET

as at 31 December 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Bridge St. Pharmacy Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board and authorised for issue on 31 March 2026 and signed on its behalf by:

Edmond McElligott
Director

Mary McElligott
Director

Bridge St. Pharmacy Limited
STATEMENT OF CHANGES IN EQUITY

as at 31 December 2025

	Called up share capital €	Retained earnings €	Total €
At 1 January 2024	20	1,576,103	1,576,123
Profit for the financial year	-	186,665	186,665
At 31 December 2024	20	1,762,768	1,762,788
Profit for the financial year	-	231,529	231,529
At 31 December 2025	20	1,994,297	1,994,317

Bridge St. Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

1. General Information

Bridge St. Pharmacy Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 490385. The registered office of the company is Bridge Street, Abbeyfeale, Co. Limerick. The principal activity of the company is the operation of a pharmacy at Abbeyfeale, Co. Limerick. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax. Turnover is recognised when the significant risks and rewards of ownership have passed to the buyer, usually on dispatch of the goods.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Long leasehold property	-	Straight line over the life of the lease
Fixtures, fittings and equipment	-	12.5% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Bridge St. Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

Employee benefits

The company provides benefits to employees, including paid holiday arrangements and staff training.

(i) Short term benefits

Short term benefits, including holiday pay and other similar non-monetary benefits, are recognised as an expense in the period in which the service is received.

The company does not operate a pension scheme.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging/(crediting):		
Depreciation of tangible assets	12,976	12,976
Government grants received	-	(6,341)
	<u> </u>	<u> </u>

4. Employees

The average monthly number of employees, including directors, during the financial year was 10, (2024 - 14).

	2025	2024
	Number	Number
Directors	2	2
Pharmacy & Customer Service	8	12
	<u> </u>	<u> </u>
	10	14
	<u> </u>	<u> </u>

Bridge St. Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

5. Tangible assets

	Long leasehold property €	Fixtures, fittings and equipment €	Total €
Cost			
At 1 January 2025	251,829	137,863	389,692
At 31 December 2025	251,829	137,863	389,692
Depreciation			
At 1 January 2025	170,212	131,318	301,530
Charge for the financial year	12,158	818	12,976
At 31 December 2025	182,370	132,136	314,506
Net book value			
At 31 December 2025	69,459	5,727	75,186
At 31 December 2024	81,617	6,545	88,162

The Long Leasehold Property cost relates to improvements to the pharmacy building which is held under a long lease from the company directors.

6. Stocks

	2025 €	2024 €
Finished goods and goods for resale	111,762	136,649

The replacement cost of stock did not differ significantly from the figures shown.

The Closing Stock figure in the Financial Year 31st December 2019 was incorrect. The value including the mark up was taken as the figure rather than the correct cost figure, No adjustments have been made in relation to this as it would just move the adjusted closing stock balance from 2019 to 2020.

7. Debtors

	2025 €	2024 €
Trade debtors	98,697	85,164
Taxation	50,617	46,680
	149,314	131,844

8. Creditors Amounts falling due within one year

	2025 €	2024 €
Trade creditors	61,920	98,627
Taxation	10,197	8,741
Directors' current accounts (Note 11)	-	6,665
Accruals	15,200	4,750
	87,317	118,783

Bridge St. Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

9. Income Statement

	2025	2024
	€	€
At 1 January 2025	1,762,768	1,576,103
Profit for the financial year	231,529	186,665
At 31 December 2025	<u>1,994,297</u>	<u>1,762,768</u>

10. Capital commitments

The company had no material capital commitments at the financial year-ended 31 December 2025.

11. Directors' remuneration and transactions

	2025	2024
	€	€
Amounts paid to third parties for the service of directors	21,382	16,089
Remuneration	114,151	108,918
	<u>135,533</u>	<u>125,007</u>

12. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

13. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 31 March 2026.